JP2023534241A5 - - Google Patents

Info

Publication number
JP2023534241A5
JP2023534241A5 JP2023502572A JP2023502572A JP2023534241A5 JP 2023534241 A5 JP2023534241 A5 JP 2023534241A5 JP 2023502572 A JP2023502572 A JP 2023502572A JP 2023502572 A JP2023502572 A JP 2023502572A JP 2023534241 A5 JP2023534241 A5 JP 2023534241A5
Authority
JP
Japan
Prior art keywords
seq
sequence
amino acid
acid sequence
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023502572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534241A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/041375 external-priority patent/WO2022015694A1/en
Publication of JP2023534241A publication Critical patent/JP2023534241A/ja
Publication of JP2023534241A5 publication Critical patent/JP2023534241A5/ja
Pending legal-status Critical Current

Links

JP2023502572A 2020-07-13 2021-07-13 G12d変異を有するrasに対するhlaクラスii拘束性drb t細胞受容体 Pending JP2023534241A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063050931P 2020-07-13 2020-07-13
US63/050,931 2020-07-13
PCT/US2021/041375 WO2022015694A1 (en) 2020-07-13 2021-07-13 Hla class ii–restricted drb t cell receptors against ras with g12d mutation

Publications (2)

Publication Number Publication Date
JP2023534241A JP2023534241A (ja) 2023-08-08
JP2023534241A5 true JP2023534241A5 (enExample) 2024-07-18

Family

ID=77227130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023502572A Pending JP2023534241A (ja) 2020-07-13 2021-07-13 G12d変異を有するrasに対するhlaクラスii拘束性drb t細胞受容体

Country Status (8)

Country Link
US (1) US20230272038A1 (enExample)
EP (1) EP4178976A1 (enExample)
JP (1) JP2023534241A (enExample)
KR (1) KR20230043881A (enExample)
CN (1) CN116322734A (enExample)
AU (1) AU2021310213A1 (enExample)
CA (1) CA3185241A1 (enExample)
WO (1) WO2022015694A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4297785A4 (en) 2021-02-26 2025-01-22 New York University COMPOSITIONS AND METHODS USING ANTIBODIES FOR BINDING TO COVALENT PEPTIDE CONJUGATES
CN118852403A (zh) * 2023-04-26 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras突变的tcr分子和细胞及其应用
CN120157754A (zh) * 2023-12-14 2025-06-17 新景智源生物科技(苏州)有限公司 Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2397741A1 (en) * 2000-01-14 2001-07-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
HRP20221183T1 (hr) * 2016-08-02 2022-12-09 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services T-stanični receptori anti-kras-g12d
CN108395479B (zh) * 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
KR20250037592A (ko) * 2017-09-20 2025-03-17 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 돌연변이된 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체

Similar Documents

Publication Publication Date Title
Clark et al. Peptide and nucleotide sequences of rat CD4 (W3/25) antigen: evidence for derivation from a structure with four immunoglobulin-related domains.
Wagtmann et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra-and intracellular domains
Orr et al. Comparison of amino acid sequences of two human histocompatibility antigens, HLA-A2 and HLA-B7: location of putative alloantigenic sites.
GB2609760A (en) HLA Class I-restricted T cell receptors against RAS with G12D mutation
RU2752528C2 (ru) Композиции и библиотеки, содержащие рекомбинантные полинуклеотиды, кодирующие Т-клеточные рецепторы, и способы применения рекомбинантных Т-клеточных рецепторов
JP2021505136A5 (enExample)
JP2023534241A5 (enExample)
JP2020534828A5 (enExample)
Mesci et al. NKR-P1 biology: from prototype to missing self
JP7735285B2 (ja) G12v突然変異rasに対するhlaクラスi拘束性t細胞受容体
JP2022523024A5 (enExample)
GB2610069A (en) HLA class II-restricted T cell receptors against RAS with G12V mutation
Fellah et al. Conserved structure of amphibian T-cell antigen receptor beta chain.
JP2023527613A5 (enExample)
JP2023544592A5 (enExample)
JP2023534241A (ja) G12d変異を有するrasに対するhlaクラスii拘束性drb t細胞受容体
GB2615010A (en) HLA class II-restricted DQ T cell receptors against RAS with G13D mutation
CA2660064A1 (en) Promiscuous pap cd4 t cell epitopes
JP2023535366A5 (enExample)
Geisler et al. Structural mutations of C-domains in members of the Ig superfamily. Consequences for the interactions between the T cell antigen receptor and the zeta 2 homodimer
Wagner et al. Structural elements underlying the high binding affinity of human cytomegalovirus UL18 to leukocyte immunoglobulin-like receptor-1
JP2023540123A5 (enExample)
JP2023535366A (ja) G12v変異を有するrasに対するhlaクラスii拘束性drb t細胞受容体
US8658177B2 (en) Promiscuous HER-2/Neu CD4 T cell epitopes
Burrows et al. Multiple class I motifs revealed by sequencing naturally processed peptides eluted from rat T cell MHC molecules